SCNI

Scinai Immunotherapeutics Ltd.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$0.43

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %7.8 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %1.5 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.

Website

Analysis (Turkish): SCNI Hissesi Caiz mi, Helal mi? Scinai Immunotherapeutics Ltd. Katılım Analizi